Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 51.90
-0.30 (-0.57%)
Jul 31, 2026, 5:30 PM CET
Basilea Pharmaceutica AG Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Basilea Pharmaceutica AG stock has a consensus rating of "Buy" and an average price target of CHF 86.88. The average 1-year stock price forecast is 67.40% higher than the current stock price, while the lowest is CHF 59.40 (+14.45%) and the highest is CHF 120.00 (+131.21%).
Price Target: CHF 86.88 (+67.40%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Apr 13, 2026.
Analyst Ratings
The average analyst rating for Basilea Pharmaceutica AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Kepler Capital | Kepler Capital | Buy Maintains CHF 69.00 → CHF 70.00 | Buy | Maintains | CHF 69.00 → CHF 70.00 | +34.87% | Apr 13, 2026 |
Financial Forecast
Revenue This Year
262.91M
from 232.38M
Increased by 13.14%
Revenue Next Year
267.47M
from 262.91M
Increased by 1.73%
EPS This Year
5.02
from 3.14
Increased by 59.93%
EPS Next Year
4.13
from 5.02
Decreased by -17.69%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CHF.